Tandem Diabetes (NASDAQ: TNDM) reported Q4 EPS of $0.16, which may not compare to the analyst estimate of $0.21. Revenue for the quarter came in at $210 million versus the consensus estimate of $198.39 million.

GUIDANCE:

Tandem Diabetes sees FY2022 revenue of $845-860 million, versus the consensus of $827.23 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.